RDUS Live signals | Maximize Profits with Getagraph.com

SELL 121459 min ago

@ $24.14

Issued: 14 Feb 2024 @ 12:18

Return: -27.01%

Previous signal: Feb 12 - 15:20

Previous signal: Buy

Return: -4.60 %

Live Chart Being Loaded With Signals

Commentary (8 May 2024 @ 16:00):

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology...

Stats
Today's Volume	169 820
Average Volume	257 100
Market Cap	495.37M
EPS	$0 ( 2024-01-04 )
Next earnings date	( $-0.690 ) 2024-06-25
Last Dividend	$0.188 ( 2023-11-10 )
Next Dividend	$0 ( N/A )
P/E	-11.47
ATR14	$0.0200 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-06	Sutherlin Michael W	Buy	526	Class A Common Stock
2024-05-06	Shoemaker Leslie L	Buy	56	Class A Common Stock
2024-05-06	Minor Glenda J	Buy	123	Class A Common Stock
2024-05-06	Jahnke David L	Buy	667	Class A Common Stock
2024-05-06	Hunter Rhonda D	Buy	295	Class A Common Stock

INSIDER POWER
-79.63
Last 94 transactions
Buy: 7 094 100 \| Sell: 18 148 047

Volume Correlation

Long: -0.04 (neutral)

Short: -0.19 (neutral)

Signal:(59.363) Neutral

Radius Health Inc Correlation

10 Most Positive Correlations
WBD	0.957
SSTI	0.954
CCSI	0.953
ESCA	0.952
MSEX	0.948
KOSS	0.947
PTE	0.947
CYXT	0.946
ACON	0.945
APPS	0.944

10 Most Negative Correlations
GXII	-0.96
ISEE	-0.959
GOGL	-0.952
HERA	-0.952
TBSAU	-0.951
CRZN	-0.948
AGGR	-0.947
TETC	-0.946
CDRO	-0.946
VPCB	-0.946

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Radius Health Inc Correlation - Currency/Commodity

0.33
( neutral )

0.51
( weak )

0.00
( neutral )

-0.05
( neutral )

-0.76
( moderate negative )

-0.60
( weak negative )

Radius Health Inc Financials

Annual	2023
Revenue:	$2.88B
Gross Profit:	$307.71M (10.68 %)
EPS:	$-0.920

FY	2023
Revenue:	$2.88B
Gross Profit:	$307.71M (10.68 %)
EPS:	$-0.920

FY	2022
Revenue:	$3.49B
Gross Profit:	$488.07M (14.00 %)
EPS:	$6.01

FY	2021
Revenue:	$229.97M
Gross Profit:	$210.82M (91.67 %)
EPS:	$-1.484

Financial Reports:

No articles found.

Radius Health Inc Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0.188 (N/A)	$0.188 (N/A)	$0.188 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Radius Health Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 8.22 - good (82.18%) | Divividend Growth Potential Score: 5.25 - Stable (5.05%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.188	2023-04-21
Last Dividend	$0.188	2023-11-10
Next Dividend	$0	N/A
Payout Date	2023-11-27
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	$0.563	--
Avg. Dividend % Per Year	0.60%	--
Score	3.79	--
Div. Sustainability Score	8.22
Div.Growth Potential Score	5.25
Div. Directional Score	6.74	--

Next Divdend (Est)
(2024-07-01)

$0.188 Estimate 22.50 %

Dividend Stability

0.60 Above Average

Dividend Score

3.79

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2023	$0.564	1.80%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.00339	1.500	9.93	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00556	1.200	9.81	10.00	[0 - 0.3]
returnOnEquityTTM	0.0111	1.500	-0.988	-1.482	[0.1 - 1]
payoutRatioTTM	2.04	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.927	0.800	5.36	4.29	[1 - 3]
quickRatioTTM	0.883	0.800	9.51	7.61	[0.8 - 2.5]
cashRatioTTM	0.0132	1.500	-1.038	-1.557	[0.2 - 2]
debtRatioTTM	0.251	-1.500	5.81	-8.71	[0 - 0.6]
interestCoverageTTM	2.18	1.000	-0.303	-0.303	[3 - 30]
operatingCashFlowPerShareTTM	6.55	2.00	7.82	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.095	2.00	9.45	10.00	[0 - 20]
debtEquityRatioTTM	0.501	-1.500	7.99	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.0989	1.000	-1.685	-1.685	[0.2 - 0.8]
operatingProfitMarginTTM	0.0117	1.000	-1.766	-1.766	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.392	1.000	8.93	8.93	[0.2 - 2]
assetTurnoverTTM	1.639	0.800	2.41	1.926	[0.5 - 2]
Total Score				8.22

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	49.44	1.000	5.11	0	[1 - 100]
returnOnEquityTTM	0.0111	2.50	-0.635	-1.482	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.095	2.00	9.64	10.00	[0 - 30]
dividendYielPercentageTTM	4.11	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.55	2.00	7.82	10.00	[0 - 30]
payoutRatioTTM	2.04	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	0.890	1.500	7.40	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0602	1.000	-0.994	0	[0.1 - 0.5]
Total Score				5.25

Radius Health Inc

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.